The new age of regenerative medicine: why stem cell therapy?
Frost & Sullivan webinar reveals stem cell therapy pipeline and treatments innovating regenerative medicine.
Cell therapy is the fastest growing segment of regenerative medicine, the majority of which is stem cell therapy. It is estimated the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.
Many factors determine the rate at which the stem cell therapy market advances. It is driven by documented successes and research indicating the potential of stem cell treatments to cure life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the world’s ageing populations.
In contrast, the stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late-stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out, as well as cGMP compliance, standardization of production processes and industry regulation changes.
The analyst briefing will explore successful stem cell therapy treatments and marketed products within the industry. It will consider the stem cell therapy pipeline including phases of clinical trials and leading indications, in addition to manufacturing considerations.
Attend this webinar to discover tangible insights on
This presentation is directed towards strategy specialists and service providers, as well as investor groups looking for emerging opportunities within the segment of regenerative medicine.
“Stem cell therapy is a new and rapidly growing industry showing phenomenal potential in its ability to be operated alone or in combination with gene and immunotherapy to cure diseases,” said Frost & Sullivan’s Transformational Health Senior Consultant, Jane Andrews. “A key barrier to market growth is manufacturing, aside from regulatory concerns, it is difficult to efficiently scale up production. The cost of goods sold for autologous production is very high and practical quality process engineering is badly needed for both autologous and allogeneic production to increase profit margins to acceptable levels.”
To attend the briefing, email Anna Zanchi, Corporate Communications ([email protected]) your full name, job title, company name, company telephone number, and company email address, website, city and country.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance